SCHEMBL207283

SCHEMBL207283

CCCCCOc1ccc(Nc2nc(Cc3ccc(OC)cc3)cs2)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 1/20 0.41
MAPT P10636 5/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
PTGS2 P35354 4/20 0.39
GALR2 O43603 1/20 0.39
RAB9A P51151 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
GAA P10253 2/20 0.39
NPC1 O15118 2/20 0.39
S1PR1 P21453 2/20 0.38
S1PR3 Q99500 2/20 0.38
S1PR2 O95136 1/20 0.38
LPAR2 Q9HBW0 1/20 0.38
P2RX3 P56373 1/20 0.38
ALOX5 P09917 1/20 0.38
NFKB1 P19838 1/20 0.38
RECQL P46063 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL205704 0.91 MAPT (0.40) PTGESMAPTMEN1KMT2ARAB9A
SCHEMBL207331 0.90 MAPT (0.46) MAPTMEN1KMT2ASMN1; SMN2S1PR1
SCHEMBL207376 0.89 CACNA1G (0.44) MAPTMEN1KMT2ASMN1; SMN2S1PR1
SCHEMBL206499 0.88 S1PR1 (0.42) MAPTMEN1KMT2APTGS2RAB9A
SCHEMBL205682 0.87 S1PR1 (0.43) MAPTMEN1KMT2APTGS2RAB9A
SCHEMBL207085 0.85 PTGS2 (0.47) MAPTMEN1KMT2APTGS2RAB9A
SCHEMBL208773 0.85 MAPT (0.44) PTGESMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL206234 0.81 KMT2A (0.50) PTGESMAPTMEN1KMT2APTGS2
SCHEMBL205547 0.80 S1PR1 (0.43) MAPTMEN1KMT2AGAAS1PR1
SCHEMBL206878 0.80 MAPT (0.44) MAPTMEN1KMT2ARAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 PTGES 2882/4885MAPT 2207/4885MEN1 3862/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 PTGES 2882/4885MAPT 2207/4885MEN1 3862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.